iBio, Inc. (IBIO)
Market Cap | 7.01M |
Revenue (ttm) | 61,000 |
Net Income (ttm) | -76.03M |
Shares Out | 22.61M |
EPS (ttm) | -8.05 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 16,539 |
Open | 0.304 |
Previous Close | 0.298 |
Day's Range | 0.302 - 0.309 |
52-Week Range | 0.260 - 8.750 |
Beta | -3.16 |
Analysts | Hold |
Price Target | 4.25 (+1,307.29%) |
Earnings Date | Nov 13, 2023 |
About IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO... [Read more]
Financial Performance
In 2022, iBio, Inc.'s revenue was $2.38 million, an increase of 0.51% compared to the previous year's $2.37 million. Losses were -$50.39 million, 114.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IBIO stock is "Hold." The 12-month stock price forecast is $4.25, which is an increase of 1,307.29% from the latest price.
News

iBio Announces Amendment to Credit Agreement with Woodforest
– Extends maturity date to December 31, 2023 – – Allows time to close pending sale of CDMO facility – BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or ...

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets –

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth
– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...

iBio Forges Research Collaboration with the National Institutes of Health
– NIH to evaluate iBio's patented AI-driven epitope steering platform for Lassa fever vaccine development –

iBio to Participate in the JMP Securities Life Sciences Conference
BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its I...

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given to...

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
– Immuno-oncology candidate discovered using iBio's AI epitope steering platform –

iBio Announces MUC16 as its Latest Immune-Oncology Target Program
- Company has directed antibodies against a specific region of MUC16 -

iBio Announces Closing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its pre...

iBio Announces Pricing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its pre...

iBio Announces Proposed Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer an...

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two pos...

iBio Announces CEO Departure
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors ...

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastP...

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline
– Positions Company for leadership in AI-powered drug discovery –

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming ® Manufa...

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPhar...

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPh...

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufac...

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPha...

iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease
iBio Inc received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company's lead COVID-19 vaccine program.

iBio Announces Participation in the H.C. Wainwright BioConnect Conference
BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPha...

iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
- Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - - Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin ...

iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
BRYAN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPh...

iBio Announces Partial Adjournment of Annual Meeting to December 22
- Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin -